International Business Expansion
SIGA achieved product revenues of approximately $6 million due to a sale to a repeat international customer in a new geographical region, signaling the broadened scope of their international business.
U.S. Government TPOXX Orders
Approximately $53 million of oral TPOXX and $9 million of IV TPOXX were delivered to the U.S. Strategic National Stockpile in April. Additionally, the U.S. government exercised an option to procure an additional $26 million of IV TPOXX, with delivery expected in 2026.
Regulatory Approvals and Pipeline Progress
TPOXX received regulatory approvals in Japan, in addition to existing approvals in the U.S., Canada, Europe, and the U.K. The PEP program is progressing with the FDA's guidance, aiming for a submission in the first half of 2026.
Financial Stability and Shareholder Returns
SIGA declared a special cash dividend of $0.60 per share, demonstrating the strength of the balance sheet and confidence in the company's future.
Strong Balance Sheet
As of March 31, 2025, SIGA had a cash balance of approximately $162 million and no debt, indicating a strong financial position.